Profile
Mr. Hood is well-known globally as a leading investment banker to the Consumer Health & Wellness industry having led or been involved in many of the better-known transactions including the sale of Bonafide Health to Pharmavite for $425 million, the sale of YouTheory to Jamieson, the sale of Metagenics to Gryphon, the sale of VÖOST to Procter & Gamble, the sale of Jarrow to New Mountain Capital, the sale of Liquid I.V. to Unilever, the sale of Persona Nutrition to Nestlé, the sale of OLLY to Unilever, the sale of GNC’s Nutra to IVC, the sale of Atrium Innovations to Nestlé for $2.4 billion, the sale of The Nature’s Bounty Company from The Carlyle Group to KKR for $3.0 billion, the sale of Holland & Barrett to Letter1 Retail for $2.3 billion, the sale of Unipharm to Takeda, the sale of Iovate to Xiwang (China) for $850 million, the sale of Jamieson to CCMP, the sale of Santa Cruz Nutrition to RoundTable Healthcare Partners, the sale of Schiff to Reckitt Benckiser for $1.4 billion, the sale of Avid Health (Lil’ Critters and Vitafusion) to Church & Dwight for $650 million, the purchase of Airborne by Schiff Nutrition and the sale of Emergen-C to Pfizer for $350 million, among others.
Prior to launching William Hood & Company in 2017, Mr. Hood worked at both a large international investment bank and a specialized boutique firm, leading practices focused on the consumer health industry. Mr. Hood began his career in 1997 at PaineWebber Investment Banking in New York.
Widely regarded as an expert in the industry, Mr. Hood is frequently invited to speak about M&A at key Health and Wellness conferences is also a contributor to both industry and financial publications including CNBC, the Wall Street Journal, Bloomberg News, WWD and Reuters among others. Mr. Hood serves on the Editorial Board of the Nutrition Business Journal.
Mr. Hood serves on the Board of Directors of Vitamin Angels and the Board of Trustees of Vitamin Angels U.K.
Sessions